key: cord-0971876-v1semau2
authors: Gubitosa, James C.; Kakar, Parul; Gerula, Christine; Nossa, Hernando; Finkel, Diana; Wong, Kristin; Khatri, Megna; Ali, Hasan
title: Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review
date: 2020-10-28
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.08.025
sha: 0977c347694f99a985e8c7f37031b7460c5e0dfc
doc_id: 971876
cord_uid: v1semau2

Remdesivir has seen extensive use during the coronavirus disease-2019 pandemic given its clinically proven efficacy against severe acute respiratory syndrome coronavirus type 2. There has been little cited regarding adverse effects. Here we present the case of a patient with marked sinus bradycardia that began acutely on initiation of remdesivir and resolved almost immediately on cessation of the drug. (Level of Difficulty: Beginner.)

. The decision was made to discontinue remdesivir and administer atropine at the bedside. Over the following days, the patient's heart rate returned to her baseline of 60 to 70 beats/min, and her QRS complex decreased to 168 ms ( Figure 3) . Chest pressure and dizziness rapidly resolved as well.

Remdesivir is a nucleoside analogue prodrug. Its Remdesivir-Associated Bradycardia in COVID-19 -2 0 2 0 : ---4

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

S. Food and Drug Administration

A randomized, controlled trial of Ebola virus disease therapeutics

Compassionate use of remdesivir for patients with severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for the treatment of Covid-19 -preliminary report

Mechanism of inhibition of Ebola virus RNAdependent RNA polymerase by remdesivir

Drug-induced mitochondrial dysfunction and cardiotoxicity

Braunwald E, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine